Sharescart Research Club logo
Products
Research
Tools
About
ChatGPT Claude Perplexity
Summarize with
ChatGPT Claude Perplexity
Join Channel
Apollo Green₹ 72 (28.6%)ASK Investment₹ 895 (-3.2%)AVPL ₹ 49 (0%)Bootes Impex₹ 775 (-8.8%)CIAL ₹ 442 (-0.5%)CSK ₹ 254 (-3.1%)ESDS Software₹ 478 (2.8%)Garuda Aerospace₹ 468 (-2.1%)Goodluck Defence₹ 385 (16%)Hero Motors₹ 325 (0%)Hinduja Leyland₹ 248 (0%)ICL Fincorp₹ 25 (0%)Incred Holdings₹ 154 (2.7%)Kineco Limited₹ 3285 (0%)Lava ₹ 60 (15.4%)Market Simplified₹ 26 (-7.1%)Matrix Gas₹ 12 (-20%)Motilal Oswal₹ 12.25 (-2%)MSEI ₹ 6.35 (-2.3%)NCDEX ₹ 368 (-1.6%)NSE ₹ 1985 (-2%)Onix Renewable₹ 68 (21.4%)OYO ₹ 23 (-4.2%)OYO Assets₹ 9.25 (-7%)Philips India₹ 1250 (0%)Polymatech Electronics₹ 56 (-3.4%)SBI Mutual₹ 768 (-0.9%)Taparia Tools₹ 6050 (0%)VCI Chemical₹ 64 (0%)Zepto ₹ 40 (-4.8%)

15 Days Price Change

Mono Pharmacare IPO

Closing In

  • days
  • Hours
  • Minutes
  • Seconds

WEBSITE Inc. Year: 2022 Industry: Trading Listed Page

Profile
Issue Size --
Profile
Price Range 26  to  28 per share
Profile
Min Investment ₹28
Profile
Lot Size 1
Profile
Face Value ₹10
Profile
Draft Prospectus
Invest Before the IPO Goes Live

Buy unlisted shares early and participate in the growth before public listing.

Profile
  • Basic Info
  • IPO Tentative Timetable
  • IPO Lot Size
  • Subscription Status
  • Financials
  • Profit & Loss
  • Balance Sheet
  • Cash Flow
  • Ratios
  • Growth Rates
  • Other info

Overview

Mono Pharmacare Ltd is a pioneering pharmaceutical company committed to advancing global healthcare. Established with a vision to enhance human well-being, Mono Pharmacare specializes in the research, development, and distribution of innovative pharmaceutical products. With a focus on cutting-edge research and development, Mono Pharmacare consistently strives to bring novel medicines and therapies to market. The company's dedicated team of scientists, researchers, and healthcare professionals work diligently to address pressing medical challenges and improve patient outcomes. Mono Pharmacare's product portfolio encompasses a wide range of therapeutic areas, including but not limited to oncology, infectious diseases, cardiovascular health, and neurology. They adhere to stringent quality standards, ensuring that their products meet the highest safety and efficacy benchmarks. Committed to global health equity, Mono Pharmacare is dedicated to providing accessible, affordable, and life-saving medications to individuals worldwide. They are at the forefront of shaping the future of healthcare through innovation and compassion. Read More

Basic Info

Face Value 10 per share

Price 26  to  28 per share

P/E (x) 15.6

Sales( Cr.) 168

PAT( Cr.) 3

EPS 1.8

Draft Prospectus

Exchange NSE-SME

Promoter

Company Promoters

Panilam Lakhatariya Supal Lakhatariya

Pre Issue Share Holding 100%

Post Issue Share Holding 42.17%

Listing Details:

Listing Price: 29

Listing Gain: 3.45%

Current Price: 12.5

Gain On Issue: 12.5 | 0%

GMP: --

GMP %: -- %

IPO Tentative Timetable

Opening Date Aug 28, 2023
Closing Date Aug 30, 2023
Allotment Aug 31, 2023
Refund Sep 01, 2023
Delivery of Shares Sep 01, 2023
Listing Date Sep 04, 2023

IPO Lot Size

Application Lots Shares Amount
Retail (Min) 1 4000 112,000
Retail (Max) 1 4000 112,000
S-HNI (Min) 2 8000 224,000
S-HNI (Max) 8 32000 896,000
B-HNI (Min) 9 36000 1,008,000

Objective of the Issue

1. To meet the working capital requirements 2. General corporate purposes 3. To meet the issue expenses.

Issue

Category Nos Bid Bid (x)
QIB 530000 5771700 10.9x
NII 2385000 19080000 8x
Retail 2385000 46269000 19.4x
EMP 0 0 0x
Total 5300000 71126000 13.4x

Net Sales (in cr.)

Total Income (in cr.)

Operating Profit (in cr.)

Net Profit (in cr.)

Shareholder Funds (in cr.)

Total Assets (in cr.)

Mono Pharmacare Profit & Loss

#(Fig in Cr.) Mar 2023 Mar 2024 Mar 2025 TTM
Net Sales 27 122 168
Other Income 0 0 1
Total Income 27 122 169
Total Expenditure 25 116 161
Operating Profit 2 6 9
Interest 1 3 4
Depreciation 0 0 0
Exceptional Income / Expenses 0 0 0
Profit Before Tax 1 3 4
Provision for Tax 0 1 1
Profit After Tax 1 2 3
Adjustments -0 -0 -0
Profit After Adjustments 1 2 3
Adjusted Earnings Per Share 0.6 1.4 1.7

Mono Pharmacare Balance Sheet

#(Fig in Cr.) Mar 2023 Mar 2024 Mar 2025
Shareholder's Funds 13 28 31
Minority's Interest 0 0 0
Borrowings 18 17 26
Other Non-Current Liabilities -0 0 0
Total Current Liabilities 31 36 53
Total Liabilities 63 81 110
Fixed Assets 1 1 1
Other Non-Current Assets 1 0 0
Total Current Assets 61 80 109
Total Assets 63 81 110

Mono Pharmacare Cash Flow

#(Fig in Cr.) Mar 2023 Mar 2024 Mar 2025
Opening Cash & Cash Equivalents 0 0 0
Cash Flow from Operating Activities -28 -9 -4
Cash Flow from Investing Activities -1 0 -0
Cash Flow from Financing Activities 30 8 5
Net Cash Inflow / Outflow 0 -0 0
Closing Cash & Cash Equivalent 0 0 1

Mono Pharmacare Ratios

# Mar 2023 Mar 2024 Mar 2025
Earnings Per Share (Rs) 0.57 1.38 1.75
CEPS(Rs) 0.61 1.46 1.83
DPS(Rs) 0 0 0
Book NAV/Share(Rs) 10.82 15.91 17.66
Core EBITDA Margin(%) 5.61 5.17 4.54
EBIT Margin(%) 6.3 5.16 5.04
Pre Tax Margin(%) 3.44 2.64 2.65
PAT Margin (%) 2.6 2.01 1.85
Cash Profit Margin (%) 2.77 2.1 1.92
ROA(%) 1.12 3.42 3.25
ROE(%) 5.24 11.85 10.47
ROCE(%) 3.16 10.22 11
Receivable days 295.76 79.75 79.66
Inventory Days 442.02 111.85 105.89
Payable days 102.92 27.14 34.13
PER(x) 0 31.9 13.21
Price/Book(x) 0 2.77 1.31
Dividend Yield(%) 0 0 0
EV/Net Sales(x) 1.94 0.97 0.56
EV/Core EBITDA(x) 30.01 18.52 10.87
Net Sales Growth(%) 0 353.27 37.6
EBIT Growth(%) 0 270.98 34.55
PAT Growth(%) 0 250.51 26.32
EPS Growth(%) 0 144.35 26.53
Debt/Equity(x) 3.03 1.47 1.72
Current Ratio(x) 1.96 2.24 2.07
Quick Ratio(x) 0.91 1.06 1.02
Interest Cover(x) 2.21 2.05 2.11
Total Debt/Mcap(x) 0 0.53 1.31

Sihora Industries Growth Rates

# 1 Year 3 Year 5 Year 10 Year
Sales CAGR 38% 0% 0% 0%
Operating Profit CAGR 50% 0% 0% 0%
PAT CAGR 50% 0% 0% 0%
# 1 Year 3 Year 5 Year 10 Year
Share Price CAGR -54% NA% NA% NA%
ROE Average 10% 9% 9% 9%
ROCE Average 11% 8% 8% 8%

Company Contact Information

Mono Pharmacare Ltd.

1 A, Krinkal Apartment Opp. Mahalaxmi Temple Paldi

IPO Lead Manager(s)

Mono Pharmacare Ltd.

Unistone Capital Pvt Ltd.

Registrar Info

Mono Pharmacare Ltd.

Frequently Asked Questions

All You Need To Know About IPO

When you leave without vesting, generally unvested ESOPs are cancelled. Vested ESOPs usually can be exercised after you depart, often within 3 to 6 months, depending on the company's ESOP plan.

For companies listed on a stock exchange, you can sell the shares any time after you exercise the ESOP option and the shares are in your demat account. If the company is unlisted or otherwise a startup, you can only sell the shares if and when the company announces a buyback or has a process for secondary sales.

Whenever you exercised your options to hold shares, you entered into a market risk situation, and if the valuation of the company drops, so do the shares.

Yes. ESOPs are valuable to the employer in that the employer is able to retain the best talent, align employee interests with company goals, and preserve cash while rewarding performance.

Wealth Icon
Don’t Miss Out on Unlisted Shares

Open your account today and gain instant access to top unlisted shares and pre-IPO opportunities.

whatsapp

Error!